Triple-negative breast cancer (TNBC) holds just about 15% of all breast tumours and subtypes of breast cancer with distinct characteristics of negative expressions for the progesterone receptor, estrogen receptor, and human epidermal growth factor receptor 2. Unfortunately, treatment options for TNBCs are minimal. Most currently available therapies proved inefficient in holding back this aggressive natural treatment of TNBC, in most cases calling for an immediate need for more effective and safer anti-TNBC agents. Based on research reported in recent years, this review presents the report's overview of anti-TNBC compounds and their efficacy, being classified according to the structures. Breast Cancer type 1 and type 2 genes (BRCA1/2) mutations are associated with TNBC. Poly (ADP-Ribose) Polymerases (PARPs) are a family of enzymes involved in numerous cellular processes, including DNA repair. PARP-1 inhibition is involved in the loss of DNA repair via BRCA-dependent mechanisms. PARP-1 inhibitors like Olaparib, Rucaparib, Niraparib, and Talazoparib have proved as promising therapeutic medications as monotherapy and in combination with cytotoxic therapy or radiotherapy in various types of cancers. This review is focused on presenting the status of therapeutics against TNBC. The critical spotlight of this review is to encapsulate the versatility and notable success of heterocyclic pharmacophores-based molecules in treating TNBC.
[http://dx.doi.org/10.1186/1471-2407-7-203] [PMID: 17976237]
[http://dx.doi.org/10.18553/jmcp.2013.19.9.799] [PMID: 24156649]
[http://dx.doi.org/10.1016/j.mito.2020.11.004] [PMID: 33220497]
[http://dx.doi.org/10.1080/14756366.2017.1417276] [PMID: 29281924]
[http://dx.doi.org/10.1021/acs.jmedchem.6b00943] [PMID: 27739679]